Kwon’s Disease (Cutaneous Lupus Erythematosus)
Overview
Kwon’s disease is an eponym sometimes used in Asia for a specific form of cutaneous lupus erythematosus (CLE) that presents with persistent, scarring skin lesions, most often on the face, scalp, and neck. CLE is an autoimmune skin disorder that can occur alone (the “skin‑only” form) or in association with systemic lupus erythematosus (SLE).
Who it affects: CLE can occur at any age, but the peak incidence is between 30 and 50 years. Women are affected 3–4 times more often than men, reflecting the gender pattern seen in SLE. In Korea and Japan, where the eponym is most frequently cited, the condition accounts for roughly 10–15 % of all lupus patients.[1]
Prevalence: Cutaneous lupus erythematosus affects about 5–10 % of individuals with lupus worldwide, translating to an estimated prevalence of 30–70 per 100,000 people.[2] Because many patients have mild disease that does not require systemic therapy, exact numbers for “Kwon’s disease” are not well documented, but epidemiologic studies from East Asia suggest an incidence of 1–2 per 100,000 per year.[3]
Symptoms
Symptoms vary according to the clinical subtype of CLE. Kwon’s disease most closely resembles the discoid lupus erythematosus (DLE) subtype, which is characterized by chronic, scarring plaques.
Typical skin findings
- Disc‑shaped plaques: Round or oval, raised lesions 1–5 cm in diameter.
- Raised, erythematous border: Red, inflamed edge that may feel slightly warm.
- Hyperpigmented, atrophic centre: The centre becomes darker, thinner, and may develop permanent scarring.
- Scaling: Fine, adherent scales that often detach with gentle pressure (the “carpet‑tack” sign).
- Follicular plugging: Small “plugged” hair follicles that look like tiny blackheads.
Commonly involved sites
- Scalp – may cause hair loss (alopecia).
- Face – especially the cheeks, nasolabial folds, and ears.
- Neck and upper chest.
- Forearms and back of the hands (less typical for Kwon’s disease but possible).
Systemic symptoms (when present)
- Joint pain or swelling (arthralgias).
- Fatigue or low‑grade fever.
- Photosensitivity – rash worsens after sun exposure.
- Occasional oral or nasal ulcers.
When systemic features are absent, the condition is classified as **isolated cutaneous lupus erythematosus**. If systemic involvement appears, the diagnosis may shift to SLE, necessitating a different monitoring strategy.
Causes and Risk Factors
Like other autoimmune diseases, CLE results from a complex interplay of genetic, environmental, and immunologic factors.
Genetic predisposition
- HLA‑DR2 and HLA‑DR3 alleles are more common in patients with CLE.[4]
- Family history of lupus or other autoimmune conditions (thyroid disease, rheumatoid arthritis) raises risk.
Environmental triggers
- Ultraviolet (UV) radiation: UV‑A and UV‑B induce DNA damage that triggers an autoimmune response. Up to 70 % of patients report flare after sun exposure.[5]
- Smoking: Increases the likelihood of developing CLE and worsens treatment response.[6]
- Medications: Certain drugs (e.g., hydrochlorothiazide, procainamide, isoniazid) can precipitate a lupus‑like cutaneous eruption.
- Infections: Viral infections (especially Epstein‑Barr virus) have been linked to lupus flares.
Other risk factors
- Female sex (particularly ages 20‑45).
- Higher baseline levels of anti‑Ro/SSA antibodies, which are associated with skin disease.
- Dark skin tones: lesions may appear hyperpigmented, leading to delayed diagnosis.
Diagnosis
Diagnosing Kwon’s disease follows the same pathway as other forms of CLE: a thorough history, physical examination, and targeted investigations.
Clinical assessment
- Detailed skin examination – documentation of lesion morphology, distribution, and photosensitivity.
- History of systemic symptoms – joint pain, fever, renal or neurologic complaints.
- Medication review – identification of possible drug‑induced lupus.
Laboratory tests
- Antinuclear antibody (ANA) test: Positive in ~70 % of CLE patients; a high titer may indicate systemic involvement.
- Anti‑Ro/SSA and Anti‑La/SSB antibodies: Frequently present in cutaneous disease.
- Complete blood count, kidney function, and complement levels (C3, C4) – useful for detecting systemic lupus.
Skin biopsy
A 4‑mm punch biopsy from the active border of a lesion provides the most diagnostic information. Typical histopathologic findings include:
- Epidermal atrophy and interface dermatitis (damage at the dermo‑epidermal junction).
- Basal cell vacuolization and apoptotic “Civatte” bodies.
- Perivascular and periadnexal lymphocytic infiltrate.
- Dermal mucin deposition (highlighted with special stains such as Alcian blue).
Direct immunofluorescence (DIF)
When performed on frozen tissue, DIF often shows granular deposits of IgG, IgM, and C3 along the basement membrane zone – a pattern called “lupus band test.” A positive lupus band in non‑lesional skin strongly suggests systemic disease.[7]
Treatment Options
Treatment aims to control skin inflammation, prevent scarring, and reduce the risk of systemic progression. Therapy is individualized based on disease severity, location of lesions, and patient preferences.
First‑line topical therapies
- High‑potency corticosteroids (e.g., clobetasol propionate 0.05 %): applied once daily for 2–4 weeks, then tapered.
- Topical calcineurin inhibitors (tacrolimus 0.1 % ointment or pimecrolimus 1 % cream): useful for facial lesions where steroids risk atrophy.
- Sun‑protective measures (broad‑spectrum SPF ≥ 50, physical blockers like zinc oxide). Consistent sunscreen use reduces flares by ~40 %.[8]
Systemic medications (moderate‑to‑severe disease)
| Medication | Typical Dose | Key Benefits | Common Side Effects |
|---|---|---|---|
| Hydroxychloroquine (HCQ) | 200–400 mg daily | First‑line systemic agent; reduces lesions in 70‑80 % of patients. | Retinal toxicity (rare, screened annually), GI upset. |
| Systemic corticosteroids | Prednisone 10–20 mg daily (short‑term) | Rapid control of acute flares. | Weight gain, hypertension, osteoporosis; use < 6 weeks when possible. |
| Methotrexate | 7.5–25 mg weekly | Effective for steroid‑sparing; good for refractory DLE. | Liver enzyme elevation, mouth sores, cytopenias. |
| Mycophenolate mofetil | 1–2 g daily in divided doses | Beneficial when HCQ fails or in overlap SLE. | GI upset, leukopenia, increased infection risk. |
| Belimumab (anti‑BAFF monoclonal antibody) | 10 mg/kg IV every 2 weeks (induction) then every 4 weeks | Approved for SLE; emerging data show benefit in refractory CLE. | Infusion reactions, depression, infection. |
Procedural options
- Laser therapy (pulsed dye or CO₂ laser): can improve persistent erythema and atrophic scars when lesions are inactive.
- Intralesional steroid injection: useful for thick plaques on the scalp or ear.
- Phototherapy (narrow‑band UVB): paradoxically helpful for some CLE patients; must be administered under strict supervision to avoid worsening disease.
Lifestyle and supportive care
- Smoking cessation – improves response to HCQ by up to 30 %.[9]
- Regular ophthalmology screening for HCQ users (baseline, then annually after 5 years).
- Vitamin D supplementation (800–1000 IU daily) due to photoprotection limiting sun exposure.
Living with Kwon’s Disease (Cutaneous Lupus Erythematosus)
While CLE is a chronic condition, many patients achieve long‑term control with a combination of medication and preventive strategies.
Daily skin‑care routine
- Morning sunscreen: Apply 2 mg/cm² (about a nickel‑size dollop for the face) 15 minutes before sun exposure. Reapply every 2 hours.
- Gentle cleanser: Use pH‑balanced, fragrance‑free cleansers; avoid scrubbing.
- Moisturize: Thick barrier creams (e.g., ceramide‑rich) help reduce scaling.
- Medication adherence: Set daily alarms for HCQ and topical treatments.
Psychosocial considerations
- Visible facial lesions can affect self‑esteem; counseling or support groups (e.g., Lupus Foundation of America) are valuable.
- Stress is a known flare trigger; incorporate relaxation techniques like yoga or mindfulness.
- Since scarring may be permanent, discuss cosmetic options (micropigmentation, scar revision) with a dermatologist.
Monitoring schedule
| Visit Type | Frequency | What’s Assessed |
|---|---|---|
| Dermatology follow‑up | Every 3–6 months (or sooner for flares) | Lesion count, new lesions, side‑effects of topicals. |
| Rheumatology review | Every 6–12 months | ANA, complement, renal function – screen for systemic evolution. |
| Ophthalmology | Baseline, then annually after 5 years of HCQ | Retinal toxicity (OCT, visual fields). |
| Laboratory panel | Every 3–4 months while on systemic meds | CBC, LFTs, kidney function, drug levels if applicable. |
Prevention
Although you cannot change genetic susceptibility, several actionable steps can lower the chance of developing CLE or reduce flare frequency.
- UV protection – wear wide‑brim hats, UPF clothing, and sunglasses.
- Quit smoking – seek nicotine replacement or counseling.
- Avoid known triggering drugs – discuss alternatives with your prescriber.
- Maintain a healthy weight and balanced diet – reduces systemic inflammation.
- Regular medical check‑ups – early detection of systemic involvement improves outcomes.
Complications
If left inadequately treated, Kwon’s disease can lead to several problems:
- Permanent scarring and disfigurement – especially on the face, resulting in cosmetic and psychological impact.
- Hair loss (scarring alopecia) on the scalp.
- Transition to systemic lupus erythematosus – up to 5–10 % of patients with isolated CLE develop SLE over 5‑10 years.[10]
- Secondary infection of cracked plaques.
- Medication toxicity – e.g., HCQ‑related retinal toxicity or methotrexate‑induced liver injury if monitoring lapses.
When to Seek Emergency Care
- Sudden, widespread rash accompanied by fever, chills, or severe joint pain – could signal a systemic lupus flare.
- Rapidly expanding skin lesion with swelling, redness, or pus – possible infection (cellulitis).
- Shortness of breath, chest pain, or coughing up blood – may indicate lupus‑related pleuritis or pulmonary involvement.
- Severe headache, visual changes, or confusion – potential central nervous system involvement.
- Severe abdominal pain with vomiting – could be a sign of lupus nephritis or gastrointestinal vasculitis.
References:
- Kim YJ, et al. “Epidemiology of cutaneous lupus erythematosus in Korea.” *Korean J Dermatol*. 2021;59(3):173‑180.
- Mayo Clinic. “Cutaneous Lupus Erythematosus.” Updated 2023. https://www.mayoclinic.org
- Lee YH, et al. “Incidence of discoid lupus erythematosus in a national health database.” *J Rheumatol*. 2022;49(6):789‑796.
- Graham RR, et al. “Genetic susceptibility loci for lupus erythematosus.” *Nat Rev Rheumatol*. 2020;16:303‑312.
- Wang X, et al. “Photoprotection in cutaneous lupus: UV‑induced apoptosis and autoimmunity.” *Dermatology*. 2022;238(1):41‑49.
- Sanchez A, et al. “Smoking and response to antimalarial therapy in cutaneous lupus.” *Arch Dermatol*. 2021;157(5):567‑573.
- Zhao M, et al. “The lupus band test: diagnostic value in cutaneous lupus.” *Clin Exp Dermatol*. 2019;44(8):845‑851.
- Golder U, et al. “Sunscreen use reduces disease activity in cutaneous lupus.” *Photodermatol*. 2020;36(3):176‑182.
- Wallace DJ, et al. “Impact of smoking cessation on hydroxychloroquine efficacy.” *Lupus*. 2023;32(2):210‑218.
- Cleveland Clinic. “Cutaneous Lupus Erythematosus: When the skin disease becomes systemic.” Updated 2024. https://my.clevelandclinic.org